Symbols

CERE(Delisted)

Cerevel Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CERE

Cerevel Therapeutics Holdings, Inc.

A clinical-stage neuroscience diseases biopharmaceutical company

Industry

Established Date

Listing Date

07/30/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

334

Fiscal Year Ends

12-31

Website

www.cerevel.com

Security Type

Common stock

Office address

222 Jacobs Street, Suite 200, Cambridge, MA 02141

Business

Introduction

Cerevel Therapeutics Holdings, Inc., is a Delaware corporation. The company is a clinical-stage biopharmaceutical company that combines a deep understanding of disease-related biology and brain neural circuits with advanced chemistry and central nervous system (CNS) targeting receptor selective pharmacology to discover and design new therapies.

Company Financials

EPS

CERE has released its 2023 Q3 earnings. EPS was reported at -0.61, versus the expected -0.63, beating expectations. The chart below visualizes how CERE has performed over recent quarters, highlighting trends in earnings surprises.